Subhashchandra Naik

Subhashchandra Naik

Auto-generated profile, based on publicly available information

Subhashchandra Naik

Comera Life Sciences, Inc., 12 Gill Street Suite 4650, Woburn, MA 01801

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Bioresource Technology
Verified
Journal Article
Closed access
SNSubhash Chandra Naik
Subhash Chandra Naik
PKPraveen Kaul
Praveen Kaul
BBBrajesh Barse
Brajesh Barse
ABAnirban Banerjee
Anirban Banerjee
UBUttam Chand Banerjee
Uttam Chand Banerjee
1

21 August 2013 in Biochemistry
Verified
Journal Article
Closed access
SNSubhashchandra Naik
Subhashchandra Naik
SBSusan Brock
Susan Brock
NANarahari Akkaladevi
Narahari Akkaladevi
JTJon Tally
Jon Tally
WMWesley Mcginn-Straub
Wesley Mcginn-Straub
MFMark Fisher
Mark Fisher

14 July 2014 in Protein Science
Verified
Journal Article
Open access
PDF file
SNSubhashchandra Naik
Subhashchandra Naik
OKOzan S. Kumru
Ozan S. Kumru
MCMelissa Cullom
Melissa Cullom
STSrivalli N. Telikepalli
Srivalli N. Telikepalli
ELElizabeth Lindboe
Elizabeth Lindboe
MFMark Fisher
Mark Fisher
The ability of a GroEL‐based bio‐layer interferometry (BLI) assay to detect structurally altered and/or aggregated species of pharmaceutically relevant proteins is demonstrated. Assay development included optimizing biotinylated‐GroEL immobilization to streptavidin biosensors, combined with biophysical and activity measurements showing native and biotinylated GroEL are both stable and active. First, acidic fibroblast growth factor (FGF‐1) was incubated under conditions known to promote (40°C) and inhibit (heparin addition) molten globule formation. Heat exposed (40°C) FGF‐1 exhibited binding to GroEL‐biosensors, which was significantly diminished in the presence of heparin. Second, a polyclonal human IgG solution containing 6–8% non‐native dimer showed an increase in higher molecular weight aggregates upon heating by size exclusion chromatography (SEC). The poly IgG solution displayed binding to GroEL‐biosensors initially with progressively increased binding upon heating. Enriched preparations of the IgG dimers or monomers showed significant binding to GroEL‐biosensors. Finally, a thermally treated IgG1 monoclonal antibody (mAb) solution also demonstrated increased GroEL‐biosensor binding, but with different kinetics. The bound complexes could be partially to fully dissociated after ATP addition (i.e., specific GroEL binding) depending on the protein, environmental stress, and the assay's experimental conditions. Transmission electron microscopy (TEM) images of GroEL‐mAb complexes, released from the biosensor, also confirmed interaction of bound complexes at the GroEL binding site with heat‐stressed mAb. Results indicate that the GroEL‐biosensor‐BLI method can detect conformationally altered and/or early aggregation states of proteins, and may potentially be useful as a rapid, stability‐indicating biosensor assay for monitoring the structural integrity and physical stability of therapeutic protein candidates.

1 March 2013 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SNSubhashchandra Naik
Subhashchandra Naik
NZNa Zhang
Na Zhang
PGPhillip Gao
Phillip Gao
MFMark Fisher
Mark Fisher
Correcting aberrant folds that develop during protein folding disease states is now an active research endeavor that is attracting increasing attention from both academic and industrial circles. One particular approach focuses on developing or identifying small molecule correctors or pharmacological chaperones that specifically stabilize the native fold. Unfortunately, the limited screening platforms available to rapidly identify or validate potential drug candidates are usually inadequate or slow because the folding disease proteins in question are often transiently folded and/or aggregationprone, complicating and/or interfering with the assay outcomes. In this review, we outline and discuss the numerous platform options currently being employed to identify small molecule therapeutics for folding diseases. Finally, we describe a new stability screening approach that is broad based and is easily applicable toward a very large number of both common and rare protein folding diseases. The label free screening method described herein couples the promiscuity of the GroEL binding to transient aggregation-prone hydrophobic folds with surface plasmon resonance enabling one to rapidly identify potential small molecule pharmacological chaperones.

2 October 2009 in Biopolymers
Verified
Journal Article
Open access
PDF file
SNSubhashchandra Naik
Subhashchandra Naik
Inamul HaqueInamul Haque
Inamul Haque
NDNick Degner
Nick Degner
BKBoris Kornilayev
Boris Kornilayev
GBGregory Bomhoff
Gregory Bomhoff
MFMark Fisher
Mark Fisher
Over the past 5 years, it has become increasingly apparent to researchers that the initial promise and excitement of using gene replacement therapies to ameliorate folding diseases are still far from being broadly or easily applicable. Because a large number of human diseases are protein folding diseases (∼30 to 50%), many researchers now realize that more directed approaches to target and reverse the fundamental misfolding reactions preceding disease are highly feasible and offer the potential of developing more targeted drug therapies. This is also true with a large number of so called orphan protein folding diseases. The development of a broad‐based general screening array method using the chaperonin as a detection platform will enable us to screen large chemical combinatorial libraries for specific ligands against the elusive transient, primary reactions that often lead to protein misfolding. This development will provide a highly desirable tool for the pharmaceutical, academic, and medical professions. © 2009 Wiley Periodicals, Inc. Biopolymers 93: 237–251, 2010. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com

28 July 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
YZYuhong Zeng
Yuhong Zeng
SNSubhashchandra Naik
Subhashchandra Naik
TTTimothy Tran
Timothy Tran
PWPhilip Wuthrich
Philip Wuthrich
NMNeal Muni
Neal Muni
RMRobert P. Mahoney
Robert P. Mahoney